ch:swissmedic

Swissmedic, Swiss Agency for Therapeutic Products

This source represents Swissmedic, Swiss Agency for Therapeutic Products and brings together its circulars.

Documents
50
Date range
Feb 1, 2016–Aug 1, 2026
Languages
4

Language share

Share of available renditions
German
27%
English
26%
French
24%
Italian
23%

All documents

  1. Guidance document Mobile technologiesSwissmedic ZL000_00_050Aug 1, 2026CircularsEN
  2. Guidance document Maintenance and updating of Annex 1Swissmedic ZL000_00_042Aug 1, 2026CircularsEN
  3. Guidance document Minimising the risk of TSESwissmedic ZL000_00_035Aug 1, 2026CircularsEN
  4. Guidance document Authorisation of allergen productSwissmedic ZL000_00_032Aug 1, 2026CircularsEN
  5. Guidance document RMP / ICH E2Swissmedic MU103_10_001Aug 1, 2026CircularsEN
  6. Guidance document Involvement of patient organisation in the review of Patient InformationSwissmedic ZL000_00_049Aug 1, 2026CircularsEN
  7. Guidance document Authorisation of human medicinal product with known active pharmaceutical substanceSwissmedic ZL101_00_018Jul 15, 2026CircularsEN
  8. Guidance document Authorisation of human medicinal product with new active substanceSwissmedic ZL101_00_005Jun 15, 2026CircularsEN
  9. Guidance document Formal requirementsSwissmedic ZL000_00_020Jun 15, 2026CircularsEN
  10. Guidance document Orphan DrugSwissmedic ZL100_00_002Jun 1, 2026CircularsEN
  11. Guidance document Project OrbisSwissmedic ZL000_00_048Jun 1, 2026CircularsEN
  12. Directory List countries with comparable control of human medicinal productsSwissmedic ZL000_00_011Jun 1, 2026CircularsEN
  13. Guidance document Packaging for human medicinal productsSwissmedic ZL000_00_021Jun 1, 2026CircularsEN
  14. Guidance document Temporary authorisation for human medicinal productsSwissmedic ZL109_00_001May 1, 2026CircularsEN
  15. Guidance document Authorisation in accordance with Art. 14 para. 1 abis-quater TPASwissmedic ZL000_00_022May 1, 2026CircularsEN
  16. Guidance document Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)Swissmedic ZL106_00_888Mar 1, 2026CircularsEN
  17. Guidance document Authorisation human medicinal product under Art. 13 TPASwissmedic ZL000_00_019Mar 1, 2026CircularsEN
  18. Guidance document Product information for human medicinal productsSwissmedic ZL000_00_027Mar 1, 2026CircularsEN
  19. Guidance document Variations and extensions HAMSwissmedic ZL300_00_001Feb 1, 2026CircularsEN
  20. Guidance document Renewal and discontinuation of authorisation or change of status (main authorisation/export licence)Swissmedic ZL201_00_001Feb 1, 2026CircularsEN
  21. Guidance document Authorisation of co-marketing medicinal productSwissmedic ZL108_00_002Feb 1, 2026CircularsEN
  22. Guidance document Document protectionSwissmedic ZL000_00_024Feb 1, 2026CircularsEN
  23. Guidance document Change name or domicile of the authorisation holderSwissmedic BW303_00_003Feb 1, 2026CircularsEN
  24. Guidance document Medicinal product nameSwissmedic ZL000_00_043Jan 1, 2026CircularsEN
  25. Guidance document Procedure with prior notificationSwissmedic ZL101_00_013Nov 1, 2025CircularsEN
  26. Guidance document No marketing / interruption of distributionSwissmedic ZL203_00_002Oct 1, 2025CircularsEN
  27. Guidance document Meetings for applicants for authorisation proceduresSwissmedic ZL105_00_003Oct 1, 2025CircularsEN
  28. Guidance document Authorisation biosimilarSwissmedic ZL101_00_012Oct 1, 2025CircularsEN
  29. Guidance document Paediatric investigation planSwissmedic ZL000_00_023Oct 1, 2025CircularsEN
  30. Guidance document Time limits for authorization applicationsSwissmedic ZL000_00_014Sep 1, 2025CircularsEN
  31. Guidance document Authorisation radiopharmaceuticalSwissmedic ZL000_00_034Aug 1, 2025CircularsEN
  32. Guidance document GMP compliance by foreign manufacturersSwissmedic ZL000_00_036Jul 14, 2025CircularsEN
  33. Guidance document Transfer of marketing authorisationSwissmedic ZL404_00_001Jul 1, 2025CircularsEN
  34. Guidance document MAGHP ProcedureSwissmedic ZL000_00_047 variant maghp_procedureMay 22, 2025CircularsEN
  35. Guidance document MAGHP ProcedureSwissmedic ZL000_00_047 variant maghp_procedure-3May 22, 2025CircularsEN
  36. Guidance document MAGHP ProcedureSwissmedic ZL000_00_047 variant maghp_procedure-2May 22, 2025CircularsEN
  37. Guidance document MAGHP ProcedureSwissmedic ZL000_00_047May 22, 2025CircularsEN
  38. Guidance document Fast-track authorisation procedureSwissmedic ZL104_00_002Apr 1, 2025CircularsEN
  39. Wegleitung Zulassung Humanarzneimittel mit bekanntem WirkstoffSwissmedic ZL101_00_007Nov 1, 2024CircularsDE
  40. Guidance document Authorisation of medicinal gasSwissmedic ZL000_00_016Oct 15, 2024CircularsEN
  41. Guidance document SwissPARSwissmedic ZL000_00_030Oct 1, 2024CircularsEN
  42. Liste pays dont le système de contrôle des BPFSwissmedic BW105_00_002 variant bw105_00_002f_vzlistedespaysdontlesystemedecontroledesbpfSep 4, 2024CircularsFR
  43. List Countries with recognised GMP control systemsSwissmedic BW105_00_002Sep 4, 2024CircularsEN
  44. Guidance document Authorisation of antiveninSwissmedic ZL000_00_033May 24, 2023CircularsEN
  45. Guidance document Authorisation of antidoteSwissmedic ZL000_00_031May 23, 2023CircularsEN
  46. Guidance document Authorisation of individual teas, cough and throat lozenges and pastilles in the notification procedure HMV4Swissmedic ZL103_00_003Jan 29, 2019CircularsEN
  47. Befristete Vertriebsbewilligung RadiopharmazeutikaSwissmedic BW107_00_002 variant bw107_00_002d_pbbefristetevertriebsbewilligungradiopharmazeutikaFeb 1, 2016CircularsDE
  48. Befristete Vertriebsbewilligung RadiopharmazeutikaSwissmedic BW107_00_002 variant bw107_00_002d_pbbefristetevertriebsbewilligungradiopharmazeutika-3Feb 1, 2016CircularsDE
  49. Befristete Vertriebsbewilligung RadiopharmazeutikaSwissmedic BW107_00_002 variant bw107_00_002d_pbbefristetevertriebsbewilligungradiopharmazeutika-2Feb 1, 2016CircularsDE
  50. Befristete Vertriebsbewilligung RadiopharmazeutikaSwissmedic BW107_00_002Feb 1, 2016CircularsDE